CN115348864A - 神经甾体的脂质前药 - Google Patents
神经甾体的脂质前药 Download PDFInfo
- Publication number
- CN115348864A CN115348864A CN202180025754.0A CN202180025754A CN115348864A CN 115348864 A CN115348864 A CN 115348864A CN 202180025754 A CN202180025754 A CN 202180025754A CN 115348864 A CN115348864 A CN 115348864A
- Authority
- CN
- China
- Prior art keywords
- acid
- disease
- nitrogen
- sulfur
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062970607P | 2020-02-05 | 2020-02-05 | |
| US62/970,607 | 2020-02-05 | ||
| US202063009533P | 2020-04-14 | 2020-04-14 | |
| US63/009,533 | 2020-04-14 | ||
| US202063070064P | 2020-08-25 | 2020-08-25 | |
| US63/070,064 | 2020-08-25 | ||
| PCT/US2021/016955 WO2021159021A1 (en) | 2020-02-05 | 2021-02-05 | Lipid prodrugs of neurosteroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115348864A true CN115348864A (zh) | 2022-11-15 |
Family
ID=77199623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180025754.0A Pending CN115348864A (zh) | 2020-02-05 | 2021-02-05 | 神经甾体的脂质前药 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20210268115A1 (https=) |
| EP (1) | EP4100017A4 (https=) |
| JP (1) | JP7810970B2 (https=) |
| KR (1) | KR20220149534A (https=) |
| CN (1) | CN115348864A (https=) |
| AU (1) | AU2021217172A1 (https=) |
| CA (1) | CA3166908A1 (https=) |
| IL (2) | IL295362A (https=) |
| WO (1) | WO2021159021A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295362A (en) | 2020-02-05 | 2022-10-01 | Puretech Lyt Inc | Lipid drug inhibitors of neurosteroids |
| IL295902A (en) * | 2020-02-27 | 2022-10-01 | Brii Biosciences Inc | Drug inhibitors of neuroactive steroids |
| CN113980029B (zh) * | 2021-10-26 | 2023-05-23 | 沈阳药科大学 | Sn38类甘油三酯前药、脂质制剂及其制备方法和应用 |
| WO2023086438A1 (en) * | 2021-11-10 | 2023-05-19 | Emory University | Prodrugs of neurosteroid analogs and uses thereof |
| EP4704905A1 (en) * | 2023-05-02 | 2026-03-11 | Sage Therapeutics, LLC | Lymphatic system-targeting compounds |
| AU2024319589A1 (en) | 2023-08-10 | 2026-01-29 | Alto Neuroscience, Inc. | Method of treating a depressive disorder and selection of patients benefiting from agomelatine based on eeg measurements |
| WO2025080689A1 (en) * | 2023-10-10 | 2025-04-17 | Seaport Therapeutics, Inc. | Lipid prodrugs of bromolysergide and uses thereof |
| WO2025106418A1 (en) * | 2023-11-13 | 2025-05-22 | Seaport Therapeutics, Inc. | Lipid prodrugs of allopregnanolone and uses thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3834132A1 (de) | 1988-10-07 | 1990-04-12 | Knoll Ag | Hydroxypropafenonglyceride |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| ATE286884T1 (de) | 1996-03-28 | 2005-01-15 | Shionogi & Co | Durch lymphe absorbierbare imidazolderivate |
| US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
| US6200530B1 (en) * | 2000-03-09 | 2001-03-13 | Michael Markels, Jr. | Method of sequestering carbon dioxide with spiral fertilization |
| US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP4324343B2 (ja) | 2001-04-24 | 2009-09-02 | 富士フイルム株式会社 | トリヨードフェニル基及びステロイド残基を有する化合物 |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| CN1867664A (zh) | 2003-10-17 | 2006-11-22 | 兰贝克赛实验室有限公司 | 使用新的链霉菌菌种生产他克莫司(fk－506) |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20090023805A1 (en) | 2006-02-13 | 2009-01-22 | Anne Claire Marrast | Method of administration |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| TW200824713A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| CN101730706B (zh) | 2007-05-11 | 2015-04-15 | 生物科技研究有限公司 | 具有神经保护和增强记忆活性的受体拮抗剂 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR100975520B1 (ko) | 2008-02-01 | 2010-08-12 | 종근당바이오 주식회사 | 마이코페놀레이트 모페틸의 개선된 제조방법 |
| EP2260052A4 (en) * | 2008-02-26 | 2013-01-16 | Univ Emory | STEROIDANALOGA FOR NEUROPROTEKTION |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| JP5757864B2 (ja) | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| US8535655B2 (en) * | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
| WO2011051967A2 (en) | 2009-10-23 | 2011-05-05 | Alkem Laboratories Ltd | Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof |
| US20110213028A1 (en) | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid mycophenolate derivatives and their uses |
| US20130245253A1 (en) | 2010-03-26 | 2013-09-19 | Department Of Veterans Affairs | Conjugated Neuroactive Steroid Compositions And Methods Of Use |
| WO2012131019A1 (en) | 2011-04-01 | 2012-10-04 | Sandoz Ag | Regioselective acylation of rapamycin at the c-42 position |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
| AU2015210833B2 (en) | 2014-02-03 | 2019-01-03 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CN117088931A (zh) * | 2014-08-12 | 2023-11-21 | 莫纳什大学 | 定向淋巴的前药 |
| US11738087B2 (en) * | 2015-09-08 | 2023-08-29 | Monash University | Lymph directing prodrugs |
| AU2016354564B2 (en) | 2015-11-12 | 2021-04-29 | Board Of Regents Of The University Of Nebraska | Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof |
| CN110418796A (zh) | 2017-03-08 | 2019-11-05 | 施万生物制药研发Ip有限责任公司 | 托法替尼(tofacitinib)的葡萄糖苷酸前药 |
| CA3068462A1 (en) | 2017-06-23 | 2019-12-27 | The Board Of Trustees Of The University Of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| US20190065544A1 (en) | 2017-08-29 | 2019-02-28 | Walmart Apollo, Llc | System and method for collaborative sharing of database information |
| CA3077739A1 (en) | 2017-08-29 | 2019-03-07 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| AR116659A1 (es) * | 2018-05-04 | 2021-06-02 | Acerus Pharmaceuticals Corp | Derivados de neuroesteroides y usos de estos |
| CA3107481A1 (en) | 2018-08-02 | 2020-02-06 | Puretech Lyt, Inc. | Lipid prodrugs of pregnane neurosteroids and uses thereof |
| WO2020176856A1 (en) | 2019-02-28 | 2020-09-03 | Puretech Lyt, Inc. | Lipid prodrugs of glucocorticoids and uses thereof |
| IL295362A (en) | 2020-02-05 | 2022-10-01 | Puretech Lyt Inc | Lipid drug inhibitors of neurosteroids |
-
2021
- 2021-02-05 IL IL295362A patent/IL295362A/en unknown
- 2021-02-05 EP EP21750039.6A patent/EP4100017A4/en active Pending
- 2021-02-05 AU AU2021217172A patent/AU2021217172A1/en active Pending
- 2021-02-05 JP JP2022547958A patent/JP7810970B2/ja active Active
- 2021-02-05 US US17/169,371 patent/US20210268115A1/en not_active Abandoned
- 2021-02-05 IL IL326763A patent/IL326763A/en unknown
- 2021-02-05 WO PCT/US2021/016955 patent/WO2021159021A1/en not_active Ceased
- 2021-02-05 CA CA3166908A patent/CA3166908A1/en active Pending
- 2021-02-05 KR KR1020227030392A patent/KR20220149534A/ko active Pending
- 2021-02-05 CN CN202180025754.0A patent/CN115348864A/zh active Pending
-
2022
- 2022-08-04 US US17/881,458 patent/US20220395513A1/en not_active Abandoned
-
2023
- 2023-06-26 US US18/341,519 patent/US11975073B2/en active Active
-
2024
- 2024-01-10 US US18/409,546 patent/US20240245788A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210268115A1 (en) | 2021-09-02 |
| US20230338552A1 (en) | 2023-10-26 |
| AU2021217172A1 (en) | 2022-09-22 |
| US20220395513A1 (en) | 2022-12-15 |
| EP4100017A4 (en) | 2024-04-10 |
| US11975073B2 (en) | 2024-05-07 |
| WO2021159021A1 (en) | 2021-08-12 |
| IL295362A (en) | 2022-10-01 |
| JP2023514147A (ja) | 2023-04-05 |
| KR20220149534A (ko) | 2022-11-08 |
| US20240245788A1 (en) | 2024-07-25 |
| CA3166908A1 (en) | 2021-08-12 |
| IL326763A (en) | 2026-04-01 |
| EP4100017A1 (en) | 2022-12-14 |
| JP7810970B2 (ja) | 2026-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115348864A (zh) | 神经甾体的脂质前药 | |
| CN112703003B (zh) | 孕烷神经类固醇的脂质前药及其用途 | |
| JP7478190B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| AU2025256194A1 (en) | Lymphatic system-directing lipid prodrugs | |
| JP2023063311A (ja) | リンパ指向プロドラッグ | |
| JP2021505591A (ja) | 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体 | |
| WO2020176856A1 (en) | Lipid prodrugs of glucocorticoids and uses thereof | |
| JP2010509204A (ja) | 脂肪酸アルコール | |
| CN111886230A (zh) | 作为acc抑制剂的吡咯衍生物 | |
| WO2025098391A1 (en) | Selective drug release from conjugates of biologically active compounds | |
| HK40084022A (en) | Lipid prodrugs of neurosteroids | |
| CN112218878A (zh) | Ntcp抑制剂 | |
| EP0527832A1 (en) | Anti-fungal bile acid derivatives | |
| HK40105719A (en) | Lymphatic system-directing lipid prodrugs | |
| HK40100603A (zh) | 定向淋巴的前药 | |
| HK40100604A (zh) | 定向淋巴的前药 | |
| TW202130619A (zh) | 硝羥喹啉前藥及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40084022 Country of ref document: HK |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20250106 Address after: U.S.A. Applicant after: Harbor Treatment Co. Country or region after: U.S.A. Applicant after: MONASH University Country or region after: Australia Address before: Massachusetts USA Applicant before: Pure technology Lyt Co.,Ltd. Country or region before: U.S.A. Applicant before: MONASH University Country or region before: Australia |
|
| TA01 | Transfer of patent application right |